MAOB and Parkinson disease: Rasagiline monotherapy has been established in early Parkinson’s disease (PD) for motor benefits in patients from both Eastern and Western countries, as is evident from a recent meta-analysis of randomized controlled clinical trials [70], and a longer duration of MAO-B inhibitor exposure is associated with reduced clinical decline in Parkinson’s disease [71].